Determination of the Dose of Antiarrhythmic Peptide in the Serum in Patients with Cardiac Disease
Abstract：To establish the standard procedure for antiarrhythmicpeptide(AAP)radioimmunoassay,to investigate the effect of cardiac disease on the secration of AAP.and to expound the mechanism of AAP secration partly, N-succinimidyl 3-(p-hroxypheny1)-propinate was used to connect 125Ⅰ and AAP,then thc immune-activity of AAP in serum was determined. The patients was divided into 3 groups:24 cases were with myocardial infarction,26 cases were with chronic heart failure, 23 cases were with atrial fibrillation.20 healthy persons were selected as control group. The dose of AAP in serum of patients were detemined and compared with that of control group.The results showed that the dose of AAP in the serum of patients with chronic heart failure(7.3+0.9 pmol/ml)or atrial fibrillation (4.72±0.98 pmol/ml)were higher than that of control group(3.9±0.6 pmol/ml)(P＜0.05). The dose of AAP in the serum of patients with myocardial infarction(4.01±0.77 pmol/ml) was the same as that of control group.The results suggested:secration of AAP demonstrated no relation to cardiac ischemia,the abnormality of blood flow dynamics could lead to the increase of AAP secration
Keywords：Antiarrhythmic peptideRadioimmunoassayMyocardialinfarctionAtrial fibrillationChronic heart failure
Publication Date：2001-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 27-29 )